CEBU CITY—Senator Imee Marcos, Senate economic affairs committee chairman urged government and private health authorities to acquire new technologies for more improved jab tests as the fear of the new COVID-19 variant Omicron spreads worldwide and to promptly take up the World Health Organization’s offer to share new blood-testing technology meant for free manufacture and easy use in rural areas.
“Mass vaccination alone is not enough for pandemic control if new variants like Delta and Omicron keep emerging. We need to get ahead of their spread through early detection and isolation, if we don’t want more blanket lockdowns and a further drag on our economy,” Marcos explained.
Marcos added that health experts are now preparing for a scenario that Omicron may render vaccines less effective, with numerous mutations detected in its spike protein that allows the virus to enter human cells.
The new blood-testing technology developer, Consejo Superior de Investigaciones Cientificas (Spanish National Research Council), has signed a licensing agreement with the WHO’s COVID-19 Technology Access Pool and the Medicine Patent Pool to waive its royalties until the last patent expires and to teach and train sub-licensees.
Rural areas that have basic laboratory infrastructure can use the new technology that detects COVID-19 antibodies activated by infection or vaccination, with results readable to the naked eye, the WHO announced.
The Philippines has fully vaccinated some 40 million or 36 percent of the country’s estimated 111 million people but is hard put to meet its 70-percent target by yearend.
Although the country’s infection rate has gone down from a high of more than 26,000 per day in September to less than 1,000 the past week, Marcos warned that “we are not immune to a pandemic resurgence now taking place in Africa and Europe.”
“With fewer Covid cases and Christmas approaching, our celebratory mood may throw caution to the wind. Let’s get those sub-licenses, increase our testing capacity, and guard our future,” Marcos said.
No comments:
Post a Comment